Journey Energy's (TSE:JOY) Weak Earnings Might Be Worse Than They Appear
Journey Energy Inc.'s (TSE:JOY) stock wasn't much affected by its recent lackluster earnings numbers. We did some digging, and we believe that investors are missing some worrying factors underlying the profit figures.
See our latest analysis for Journey Energy
To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. As it happens, Journey Energy issued 9.4% more new shares over the last year. That means its earnings are split among a greater number of shares. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. Check out Journey Energy's historical EPS growth by clicking on this link.
Journey Energy's net profit dropped by 95% per year over the last three years. And even focusing only on the last twelve months, we see profit is down 67%. Like a sack of potatoes thrown from a delivery truck, EPS fell harder, down 69% in the same period. And so, you can see quite clearly that dilution is influencing shareholder earnings.
In the long term, if Journey Energy's earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Journey Energy.
Alongside that dilution, it's also important to note that Journey Energy's profit was boosted by unusual items worth CA$5.7m in the last twelve months. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. We can see that Journey Energy's positive unusual items were quite significant relative to its profit in the year to December 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
In its last report Journey Energy benefitted from unusual items which boosted its profit, which could make the profit seem better than it really is on a sustainable basis. And furthermore, it went and issued plenty of new shares, ensuring that each shareholder (who did not tip more money in) now owns a smaller proportion of the company. For the reasons mentioned above, we think that a perfunctory glance at Journey Energy's statutory profits might make it look better than it really is on an underlying level. If you'd like to know more about Journey Energy as a business, it's important to be aware of any risks it's facing. While conducting our analysis, we found that Journey Energy has 3 warning signs and it would be unwise to ignore these.
In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Asian Dividend Stocks To Watch In 2023
As global markets navigate a complex landscape of trade tensions and economic shifts, Asian indices have shown resilience, with Chinese stocks gaining momentum amid expectations of government stimulus. In this environment, dividend stocks in Asia present an intriguing opportunity for investors seeking steady income streams, particularly as companies with strong fundamentals and reliable payout histories can offer stability amidst market fluctuations. Name Dividend Yield Dividend Rating Yamato Kogyo (TSE:5444) 4.44% ★★★★★★ Wuliangye YibinLtd (SZSE:000858) 5.07% ★★★★★★ Nissan Chemical (TSE:4021) 4.20% ★★★★★★ Japan Excellent (TSE:8987) 4.39% ★★★★★★ HUAYU Automotive Systems (SHSE:600741) 4.50% ★★★★★★ Guangxi LiuYao Group (SHSE:603368) 4.42% ★★★★★★ DoshishaLtd (TSE:7483) 4.18% ★★★★★★ Daicel (TSE:4202) 5.01% ★★★★★★ CAC Holdings (TSE:4725) 4.87% ★★★★★★ Asian Terminals (PSE:ATI) 6.37% ★★★★★★ Click here to see the full list of 1240 stocks from our Top Asian Dividend Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: GS Holdings Corp., along with its subsidiaries, operates in the energy, power generation, retail, service, construction, and infrastructure sectors with a market cap of ₩4.49 trillion. Operations: GS Holdings Corp.'s revenue primarily comes from its Distribution segment at ₩11.39 trillion, followed by the Gas and Electric Business at ₩7.43 trillion, Trade at ₩3.91 trillion, with an adjustment for Cross-Sector Revenue of -₩0.21 trillion. Dividend Yield: 5.7% GS Holdings offers a compelling dividend profile with its payouts well-covered by earnings (63.7% payout ratio) and cash flows (47.4% cash payout ratio). The dividend yield of 5.68% ranks in the top 25% of South Korean market payers, though the company has only a three-year history of dividends, indicating limited track record stability. Despite recent profit margin declines, GS Holdings trades at a significant discount to fair value estimates and peers, enhancing its attractiveness as a value investment. Take a closer look at GS Holdings' potential here in our dividend report. Our valuation report here indicates GS Holdings may be undervalued. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Shandong Weigao Group Medical Polymer Company Limited is involved in the R&D, production, wholesale, and sale of medical devices both in China and internationally, with a market cap of HK$26.97 billion. Operations: Shandong Weigao Group Medical Polymer's revenue is primarily derived from its Medical Device Products segment at CN¥6.60 billion, followed by Interventional Products at CN¥1.98 billion, Pharma Packaging Products at CN¥2.28 billion, Orthopaedic Products at CN¥1.44 billion, and Blood Management Products at CN¥876.78 million. Dividend Yield: 4% Shandong Weigao Group Medical Polymer provides a mixed dividend profile, with payouts covered by earnings (47.3% payout ratio) and cash flows (45.9% cash payout ratio), yet its dividend history has been volatile over the past decade. Recent shareholder-approved buybacks aim to enhance net asset value and earnings per share, potentially bolstering future dividends. The company trades at a considerable discount to fair value estimates, though its current yield of 3.98% lags behind top-tier payers in Hong Kong. Click here and access our complete dividend analysis report to understand the dynamics of Shandong Weigao Group Medical Polymer. Our valuation report unveils the possibility Shandong Weigao Group Medical Polymer's shares may be trading at a discount. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Dongfang Electric Corporation Limited designs, develops, manufactures, and sells power generation equipment in China and internationally with a market cap of HK$60.10 billion. Operations: Dongfang Electric Corporation Limited's revenue segments include CN¥45.23 billion from thermal power equipment, CN¥12.78 billion from hydropower equipment, CN¥5.67 billion from wind power equipment, and CN¥3.45 billion from nuclear power equipment. Dividend Yield: 3.6% Dongfang Electric's dividends are supported by earnings (43.1% payout ratio) and cash flows (59.2% cash payout ratio), though its dividend history has been unstable over the last decade. Recent earnings reports show improved financial performance, with Q1 2025 net income rising to CNY 1.15 billion from CNY 905.75 million a year earlier, yet the proposed final dividend for 2024 decreased, reflecting ongoing volatility in payouts despite potential growth prospects. Get an in-depth perspective on Dongfang Electric's performance by reading our dividend report here. The valuation report we've compiled suggests that Dongfang Electric's current price could be inflated. Take a closer look at our Top Asian Dividend Stocks list of 1240 companies by clicking here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A078930 SEHK:1066 and SEHK:1072. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@